Medacta Group Toekomstige groei

Future criteriumcontroles 3/6

Medacta Group zal naar verwachting groeien in winst en omzet met respectievelijk 18.4% en 11.9% per jaar. De winst per aandeel zal naar verwachting groeien met 21% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 19.5% zijn.

Belangrijke informatie

18.4%

Groei van de winst

21.0%

Groei van de winst per aandeel

Medical Equipment winstgroei14.9%
Inkomstengroei11.9%
Toekomstig rendement op eigen vermogen19.5%
Dekking van analisten

Good

Laatst bijgewerkt15 Nov 2024

Recente toekomstige groei-updates

Recent updates

The Price Is Right For Medacta Group SA (VTX:MOVE)

Nov 22
The Price Is Right For Medacta Group SA (VTX:MOVE)

Is Medacta Group (VTX:MOVE) A Risky Investment?

Oct 14
Is Medacta Group (VTX:MOVE) A Risky Investment?

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

Sep 06
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Aug 21
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Aug 06
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Jun 20
Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Apr 17
Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Mar 29
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Feb 22
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Feb 07
Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Dec 18
Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Dec 04
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Nov 15
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Oct 30
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Oct 17
If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Sep 29
Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Aug 11
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Jul 27
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

Jul 03
Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Apr 28
At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Is Medacta Group (VTX:MOVE) A Risky Investment?

Apr 08
Is Medacta Group (VTX:MOVE) A Risky Investment?

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dec 25
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Dec 09
Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Nov 09
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

Sep 16
Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Aug 20
The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Jul 02
Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

May 28
Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

May 12
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Mar 31
These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Mar 17
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Feb 07
Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Dec 10
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Nov 05
Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Sep 30
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Aug 26
Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Jul 20
Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

May 19
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Apr 05
We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Mar 02
What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

Feb 02
Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Jan 12
The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Dec 21
Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

Dec 03
Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

Winst- en omzetgroeiprognoses

SWX:MOVE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026746100441506
12/31/202566686341336
12/31/202458872101086
6/30/202454456-1480N/A
3/31/202452852-1077N/A
12/31/202351147-675N/A
9/30/202349649278N/A
6/30/202348150980N/A
3/31/202345948877N/A
12/31/202243746774N/A
9/30/202241747472N/A
6/30/202239747270N/A
3/31/202238049162N/A
12/31/202136352-154N/A
9/30/2021354541158N/A
6/30/2021345572263N/A
3/31/2021324472261N/A
12/31/2020302372260N/A
9/30/202029824950N/A
6/30/202029410-540N/A
3/31/202030211-741N/A
12/31/201931112-943N/A
9/30/201930122-346N/A
6/30/201929133350N/A
3/31/201928239758N/A
12/31/2018273461166N/A
12/31/201724533N/A52N/A
12/31/201621939N/A56N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei MOVE ( 18.4% per jaar) ligt boven de spaarquote ( 0.3% ).

Winst versus markt: De winst van MOVE ( 18.4% per jaar) zal naar verwachting sneller groeien dan de Swiss markt ( 11.3% per jaar).

Hoge groeiwinsten: De winst van MOVE zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van MOVE ( 11.9% per jaar) zal naar verwachting sneller groeien dan de markt Swiss ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van MOVE ( 11.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen MOVE zal naar verwachting over 3 jaar laag zijn ( 19.5 %).


Ontdek groeibedrijven